Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -134.62% | 256.06% | 1.31% | -1,892.17% | -81.48% |
| Total Depreciation and Amortization | -2.34% | 6.31% | -11.54% | -0.93% | 11.56% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | -- |
| Total Other Non-Cash Items | 746.04% | -135.42% | -16.08% | 388.05% | 172.61% |
| Change in Net Operating Assets | 24.25% | -263.95% | -14.05% | -139.87% | -141.35% |
| Cash from Operations | 277.13% | 468.34% | -173.02% | -53.67% | 49.77% |
| Capital Expenditure | 71.06% | -- | 100.00% | 88.13% | -92.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | 618.95% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | -- |
| Cash from Investing | 71.06% | -- | -100.00% | 101.06% | -312.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2,542.80% | 19.06% | 39.79% | -83.36% | 56.38% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -2,915.11% | 29.05% | 39.79% | -83.36% | 56.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.48% | 340.84% | -208.94% | -11.68% | 0.88% |